Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 10 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 15 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 2.5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 20 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 25 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

teva israel ltd - lenalidomide as hydrochloride hydrate - hard capsule - lenalidomide as hydrochloride hydrate 7.5 mg - lenalidomide - multiple myeloma (mm): lenalidomide teva is indicated for the treatment of multiple myeloma.myelodysplastic syndromes: lenalidomide teva is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.lenalidomide teva 7.5 mg is not indicated for treatment in mds.mantle cell lymphoma:lenalidomide teva is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphoma:lenalidomide teva in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: croscarmellose sodium gelatin indigo carmine iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide devatis is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide devatis is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide devatis in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

Malta - English - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - lenalidomide - hard capsule - lenalidomide 2.5 mg - immunosuppressants

Malta - English - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - lenalidomide - hard capsule - lenalidomide 5 mg - immunosuppressants